Navigation Links
Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials

sinesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

XIENCE is a registered trademark of Abbott. TAXUS and PROMUS are registered trademarks of Boston Scientific.

CONTACT: Media, Karin Bauer Aranaz, +1-650-868-2999, or Financial, TinaVentura, +1-847-935-9390, both of Abbott

Web site: http://www.abbott.com/http://www.abbottvascular.com/presskit/

Ticker Symbol: (NYSE:ABT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/14/2014)... July 14, 2014 A new Manhattan ... Decision Makers 2014, finds that members of ... care organizations (MCOs) and pharmacy benefits managers (PBMs) ... information.  A majority of formulary decision makers report ... during the formulary decision making process today than ...
(Date:7/14/2014)... July 14, 2014  Clinicians at a leading ... have become the first in the country to ... using an upgraded Clinac® medical linear accelerator from ... been enhanced with High Intensity Mode dose delivery ... Institute to shorten treatment times and deliver stereotactic ...
(Date:7/14/2014)... FAIRHOPE, Ala. , July 14, 2014  Patients ... of patients as Express Scripts and other major pharmacy ... coverage. The cuts will directly impact millions of patients ... of medical conditions, including persistent pain from cancer, diabetes ... will begin notifying some patients on July 15. ...
Breaking Medicine Technology:Digital Resources Play Critical Role in Formulary Decision Making 2Digital Resources Play Critical Role in Formulary Decision Making 3Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 2Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4
... WASHINGTON, Nov. 20 Pharmaceutical,researchers are testing 92 ... related conditions, according to a report released today ... December,1 marks the 20th anniversary of "World AIDS ... the 1988 World Summit of Ministers of Health ...
... in Non-Small Cell Lung Cancer Expected to Inform ... for Experimental Cancer Treatment, MOUNTAIN VIEW, Calif., ... a leading provider of software,strategic consulting, and regulatory ... its Strategic Consulting Services Group,is using a quantitative ...
Cached Medicine Technology:92 Medicines and Vaccines now in Development for HIV/AIDS 292 Medicines and Vaccines now in Development for HIV/AIDS 3Pharsight Uses FDA Disease Model to Support Oncology Drug Development 2Pharsight Uses FDA Disease Model to Support Oncology Drug Development 3
(Date:7/14/2014)... Europe’s market for cardiac surgery devices ... by 2020, with the transcatheter heart valve devices sector ... transcatheter mitral valve repair (TMVR) segments) fuelling this growth. ... ?urrently the only THVI product on the market. However, ... and are anticipated to get CE approval by end-2020. ...
(Date:7/14/2014)... Since the announcement of the merger to form AAG HealthGAINS ... has been traveling to our network of facilities nationwide to ... our proprietary Maximum Sexual Performance Program for men and women. ... location on July 22nd, AAG Health NYC, 65 Broadway, Suite ... train our staff, and be on hand to answer patient ...
(Date:7/14/2014)... The North America Biostimulant Market report defines and ... and forecast of revenue. The biostimulants market in North ... in 2013 to $490.1 million by 2018, at a ... through the TOC of the North America Biostimulant Market ... provided. This also provides a glimpse of the segmentation ...
(Date:7/14/2014)... 14, 2014 Employers looking to ... employees with more benefit options must understand how ... online marketplaces, are the future of employee benefits. ... Jersey (Horizon BCBSNJ) is offering a free webinar, ... Offering More Options, to demonstrate how HorizonSelect, its ...
(Date:7/14/2014)... Continuing a steady trend of growth ... the heels of first-quarter success with Orange Regional Medical ... company founded by CEO and President Dr. Virginia Feldman ... three new members. Robert Poltenovage has joined ... John Steele, LPN and Angelica D’Amico have joined the ...
Breaking Medicine News(10 mins):Health News:Europe Cardiac Surgery Device Market Value to Go Beyond USD 3.4 Bn by 2020, According to iData Research Study Available at MarketPublishers.com 2Health News:Europe Cardiac Surgery Device Market Value to Go Beyond USD 3.4 Bn by 2020, According to iData Research Study Available at MarketPublishers.com 3Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 2Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 3Health News:No Cost Employer Webinar to Demonstrate How Private Exchanges Can Lower Benefit Costs While Increasing Options for Employees 2Health News:Nexus Health Resources Continues Growth, Outstanding Health Care Coordination With Addition of Three New Team Members 2
... carcinoma in situDCISwho later develop invasive breast cancer in ... from breast cancer than those who do not develop ... 11 in the Journal of the National Cancer ... have compared breast conserving surgery (lumpectomy) to mastectomy and ...
... , FRIDAY, March 11 (HealthDay News) -- Taking ... but mostly in people at increased risk for the ... in their blood, according to a new study. ... or other nonsteroidal anti-inflammatory drugs (NSAIDs) have a reduced ...
... March 11 (HealthDay News) -- Watching your team win a ... be thrilling, but there may be a drawback: aggressive, testosterone-fueled ... found that traffic deaths at the game site and the ... game is over. Researchers at North Carolina State University ...
... are a burning issue. A straightforward guide to a closer understanding ... 2011). The Dose Makes the Poison: A Plain-Language Guide to Toxicology, ... leads to a distortion in many people,s conceptions of toxins and ... We are exposed to media reports on a daily basis of ...
... DETROIT Theories have long proposed that testosterone influences ... a recent study at Wayne State University give a ... mating behavior, and how testosterone is associated with dominance ... of an attractive woman. The study engaged ...
... causes AIDS invades human immune cells and causes ... can then infect new cells. A research team led ... Priv.-Doz. Dr. Barbara Mller of Heidelberg University Hospital have ... infected cell in virion release, and discovered that the ...
Cached Medicine News:Health News:DCIS patients who get invasive breast cancer have higher mortality 2Health News:Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People 2Health News:Fans of Winning Teams Linked to Fatal Crashes 2Health News:'The Dose Makes the Poison: A Plain-Language Guide to Toxicology,' 3rd Edition 2Health News:Wayne State study links testosterone with men's ability to 'woo' potential mates 2Health News:Pushing HIV out the door: How host factors aid in the release of HIV particles 2
LCD monitors....
This monitor is designed specifically for medical applications and is UL2601-1 listed....
Standard arthroscope with telescope (4 mm) for large joints....
A lower cost alternative to the flagship A3, the A1 retains the essential characteristics of high quality image, simplicity of operation and reliability....
Medicine Products: